Mithra Wins BelMid Company of the Year 2018

Liège, Belgium, 18 January 2019 - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, has been awarded BelMid Company of the Year 2018 by Euronext Brussels at its annual New Year's Ceremony held in Brussels last night.

François Fornieri, CEO Mithra Women's Health, commented: "In 2015 when we listed on Euronext Brussels, we said that 2018 would be a key year for Mithra and we have delivered. I am very proud and pleased for Mithra's shareholders, team and company. 2019 will be an even better year and I look forward to working with the team to make sure we deliver on our strategy."

The annual ceremony recognises the best performing companies in Belgium and is attended by 600 key stakeholders. BelMid Company of the Year is awarded to a company that has demonstrated the highest relative increase in market capitalisation. The award was presented by the Belgian Minister of Finance, Alexander De Croo.

********

For more information, please contact:

Investor Relations & Press

François Fornieri (CEO): +32 4 349 28 22 Jean-Manuel Fontaine (PRO): +32 (0)476 96 54 59investorrelations@mithra.com

Consilium Strategic Communications

Susan Stuart, Olivia Manser, Melissa Gardinermithra@consilium-comms.com +44 2 037 095 700

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra's unique native estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at:www.mithra.com

Important Information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To receive our press releases by email, please subscribe to our mailing list oninvestors.mithra.com

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 18 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 January 2019 08:23:07 UTC